Union Health Minister JP Nadda recently assessed the Indian Pharmacopoeia Commission’s advancements to ensure medicine quality. The Commission’s pharmacovigilance efforts are crucial for safeguarding patient well-being and regulating the quality of Indian medicines for both local and global markets. Nadda highlighted these efforts as a step towards India’s scientific self-reliance, emphasizing the importance of pharmaceutical quality and safety.
The Health Ministry praised the Indian Pharmacopoeia Commission for enhancing pharmacopeial standards, pharmacovigilance systems, and regulatory science. This initiative plays a significant role in maintaining the quality, safety, and effectiveness of medicines for both Indian citizens and the global community. These endeavors align with the vision of Prime Minister Narendra Modi’s Atmanirbhar Bharat, reflecting India’s growing scientific independence.
In a recent development, the Indian Pharmacopoeia Commission in Ghaziabad signed three Memoranda of Understanding (MoUs) with various healthcare bodies in Nagaland. These collaborations aim to bolster pharmacovigilance, promote adverse event reporting, enhance stakeholder capacity, and ensure safe medicine usage across healthcare facilities in Nagaland. Notably, the MoU with the Nagaland Drugs Control Administration marks a significant step in the Commission’s regional partnerships.
During the National Pharmacovigilance Week in September, the Indian Pharmacopoeia Commission encouraged active participation from healthcare professionals and patients in reporting adverse drug reactions. This week-long campaign sought to raise awareness among healthcare stakeholders and the public regarding the simplified digital platforms available for reporting adverse drug reactions. The Commission’s efforts underscore the importance of pharmacovigilance in ensuring medication safety and efficacy.
